🧬ICD-10 CM C51.9 - Malignant Neoplasm of Vulva, Unspecified

ICD-10-CM Full Descriptor: Malignant neoplasm of vulva, unspecified

⚠️ Code Type Note: C51.9 is an ICD-10-CM diagnosis code, not a CPT procedure code. Concepts such as wRVU, global period, and assistant surgeon payable apply to associated CPT procedure codes (see Associated Procedures section below), not to the diagnosis code itself. HCC mapping, MS-DRG assignment, and POA indicator requirements are the primary reimbursement and compliance elements relevant to C51.9 in the inpatient coding context.

📋 Diagnosis Overview

C51.9 identifies a primary malignant neoplasm of the vulva when the specific anatomic sub-site of the vulva involved by the malignancy is not documented or cannot be determined from the available clinical documentation. The vulva comprises the external female genitalia — including the labia majora, labia minora, clitoris, vestibule, Bartholin’s glands, and related skin and mucous membrane structures — and malignancies arising from these structures are collectively classified under the C51.x code category.

The unspecified designation (C51.9) should be used only when the provider’s documentation does not specify the sub-site involved, or when the tumor overlaps multiple sub-sites in a manner that cannot be classified to a single sub-site. When documentation specifies the anatomic site of involvement (e.g., “carcinoma of the labia majora” or “squamous cell carcinoma of the clitoris”), a more specific code from the C51 category should be selected over C51.9.

🔬 Clinical Background

Histology

The vast majority (approximately 90%) of vulvar malignancies are squamous cell carcinomas (SCC), arising from the squamous epithelium of the vulvar skin and mucosa. Additional histologic subtypes encountered in clinical practice include:

Melanoma (~5%) — second most common; arises from melanocytes in vulvar skin
Adenocarcinoma — including Bartholin gland adenocarcinoma and Paget’s disease of the vulva with underlying adenocarcinoma
Basal cell carcinoma — less aggressive; rarely metastasizes; predominantly labium majus
Verrucous carcinoma — a well-differentiated SCC variant; locally invasive; low metastatic potential
Sarcoma — rare; includes leiomyosarcoma and rhabdomyosarcoma

Coding Note: ICD-10-CM does not distinguish histologic subtypes within C51.9. All primary malignant neoplasms of the unspecified vulva — regardless of histology — are captured by C51.9. Histologic type is clinically important for treatment planning and pathology coding (88305, 88307, etc.) but does not alter ICD-10-CM code selection at the C51.x level.

Etiology & Risk Factors

HPV-related pathway (~40% of vulvar SCCs): High-risk HPV types (16, 18) → vulvar intraepithelial neoplasia (VIN) → invasive SCC; typically younger patients, multifocal disease
HPV-independent pathway (~60%): Chronic inflammatory conditions — lichen sclerosus, lichen planus — → differentiated VIN → invasive SCC; typically older patients, unifocal disease
Additional risk factors: immunosuppression, prior cervical/vaginal malignancy, smoking, prior pelvic radiation

FIGO Staging (Clinical Context — Documented by Physician)

ICD-10-CM does not contain FIGO or TNM stage-specific codes for vulvar cancer. Stage is a clinical/pathologic designation documented by the treating physician and does not independently change the ICD-10-CM code selection. FIGO staging is used clinically to guide treatment:

FIGO Stage	Description
I	Tumor confined to vulva; nodes negative
IA	≤2 cm, stromal invasion ≤1 mm
IB	>2 cm OR stromal invasion >1 mm
II	Tumor of any size with extension to perineum, lower 1/3 vagina or urethra; nodes negative
III	Positive inguinofemoral lymph nodes
IIIA	1-2 node metastases <5 mm, or 1 node ≥5 mm
IIIB	≥2 node metastases ≥5 mm, or ≥3 node metastases <5 mm
IIIC	Nodes with extracapsular spread
IVA	Upper urethra/vagina, bladder/rectal mucosa, fixed to pelvic bone, or fixed/ulcerated nodes
IVB	Any distant metastasis including pelvic lymph nodes

Urologic Relevance: Locally advanced vulvar cancers (FIGO Stage IVA) may involve the urethra, bladder neck, or bladder mucosa, creating direct overlap with urologic coding and management. When urethral or bladder involvement is documented, additional codes for secondary malignant involvement of these structures should be captured (e.g., C79.19 secondary malignant neoplasm of other urinary organs).

🏷️ HCC Risk Adjustment

Model	HCC Category	Description	RAF Impact
CMS-HCC v24	HCC 11	Colorectal, Bladder, and Other Cancers	High
CMS-HCC v28	HCC 17	Lung and Other Severe Cancers (restructured grouping — verify current mapping)	High

HCC 11 (v24) / HCC 17 (v28): Active vulvar malignancy carries significant risk-adjustment weight under both the v24 and restructured v28 CMS-HCC models. This RAF impact reflects the substantial expected healthcare resource utilization associated with active cancer — surgical treatment, radiation, chemotherapy, reconstruction, and ongoing surveillance. C51.9 must be coded and reported at every qualifying encounter where the malignancy is being actively managed, treated, or monitored. Under Medicare Advantage risk adjustment, this diagnosis drives meaningful premium adjustment for health plans covering patients with active vulvar cancer.

⚠️ v28 Mapping Verification: CMS-HCC v28 introduced a substantially reorganized cancer category structure. The specific HCC assignment for C51.9 under v28 should be verified against the current-year CMS HCC mapping crosswalk file, as groupings were significantly revised from v24.¹

Metastatic Upgrade to HCC 8: If vulvar cancer has spread to distant sites (lymph nodes beyond regional, liver, lung, bone, etc.), metastatic codes (C77.x, C78.x, C79.x) map to HCC 8 (Metastatic Cancer and Acute Leukemia) under v24 — a substantially higher RAF coefficient than HCC 11. Accurate capture of metastatic disease is critical for RAF accuracy.

🌳 Code Tree - Malignant Neoplasms of the Vulva (C51 Category)

C51 - Malignant Neoplasm of Vulva
│
├── C51.0 - Malignant neoplasm of labium majus
│               (Includes: outer lip of vulva; greater vestibular [Bartholin's] gland
│                if malignancy arises from skin of labium majus)
│
├── C51.1 - Malignant neoplasm of labium minus
│               (Inner folds of the vulva; thin skin folds medial to labia majora)
│
├── C51.2 - Malignant neoplasm of clitoris
│               (Erectile organ at apex of vulva)
│
├── C51.8 - Malignant neoplasm of overlapping sites of vulva
│               (Tumor extends across multiple sub-sites; cannot be classified
│                to any single sub-site above; "overlapping lesion of vulva")
│
└── C51.9 ◄ THIS CODE - Malignant neoplasm of vulva, unspecified
                (Use when sub-site not specified in documentation;
                 most specific code should always be used when documentation allows)

Code Hierarchy — Female External Genitalia Malignancies (Broader Context)

Malignant Neoplasms of Female Genital Organs (C51-C58)
│
├── C51.x - Vulva ◄ This category
├── C52 - Vagina
├── C53.x - Cervix uteri
│   ├── C53.0 - Endocervix
│   ├── C53.1 - Exocervix
│   ├── C53.8 - Overlapping sites of cervix
│   └── C53.9 - Cervix uteri, unspecified
├── C54.x - Corpus uteri
│   ├── C54.0 - Isthmus uteri
│   ├── C54.1 - Endometrium
│   ├── C54.2 - Myometrium
│   ├── C54.3 - Fundus uteri
│   ├── C54.8 - Overlapping sites of corpus uteri
│   └── C54.9 - Corpus uteri, unspecified
├── C55 - Uterus, part unspecified
├── C56.x - Ovary
│   ├── C56.1 - Right ovary
│   ├── C56.2 - Left ovary
│   ├── C56.3 - Bilateral ovaries
│   └── C56.9 - Ovary, unspecified
├── C57.x - Other/unspecified female genital organs
│   ├── C57.00 - Fallopian tube, unspecified
│   ├── C57.7 - Other specified female genital organs (Bartholin's gland)
│   └── C57.9 - Female genital organ, unspecified
└── C58 - Placenta (choriocarcinoma)

Vulvar Intraepithelial Neoplasia (Pre-malignant — NOT C51.9)

Spectrum of Vulvar Disease (Lowest to Highest Grade)
│
├── Lichen sclerosus / Lichen planus (inflammatory precursor)
│   └── L90.0 - Lichen sclerosus et atrophicus
│
├── Vulvar Intraepithelial Neoplasia (VIN) - Pre-malignant
│   ├── N90.0 - VIN I (mild dysplasia)
│   ├── N90.1 - VIN II (moderate dysplasia)
│   └── N90.2 - VIN III (severe dysplasia; carcinoma in situ)
│       └── [[D07.1 - Carcinoma in situ of vulva
│               (High-grade VIN / HSIL-V; NOT yet invasive; use D07.1 NOT C51.9)
│
└── Invasive Malignancy — Code C51.x ◄
    ├── C51.0 - Labium majus
    ├── C51.1 - Labium minus
    ├── C51.2 - Clitoris
    ├── C51.8 - Overlapping sites
    └── C51.9 ◄ THIS CODE - Unspecified site

⚠️ Critical Distinction — In Situ vs. Invasive:

D07.1 (carcinoma in situ of vulva / VIN III / HSIL-V) = pre-malignant; no basement membrane invasion; NOT coded as C51.9

C51.9 = invasive malignancy; basement membrane has been breached; definitive cancer diagnosis

The distinction between in situ (D07.1) and invasive (C51.9) malignancy is clinically and pathologically determined. Do not assign C51.9 based on a VIN III diagnosis alone — require pathology confirmation of invasion. For inpatient coding, the physician’s documented diagnosis of “invasive carcinoma” or “malignant neoplasm” of the vulva supports C51.9.

🏥 Commonly Associated ICD-10-CM Codes

Regional & Distant Metastatic Disease

ICD-10-CM Code	Description	HCC v24	HCC v28
C77.4	Secondary malignant neoplasm of inguinal and lower limb lymph nodes	HCC 8	HCC 8
C77.5	Secondary malignant neoplasm of intrapelvic lymph nodes	HCC 8	HCC 8
C77.8	Secondary malignant neoplasm of lymph nodes of multiple regions	HCC 8	HCC 8
C77.9	Secondary malignant neoplasm of lymph node, unspecified	HCC 8	HCC 8
C78.89	Secondary malignant neoplasm of other digestive organs	HCC 8	HCC 8
C79.11	Secondary malignant neoplasm of bladder	HCC 8	HCC 8
C79.19	Secondary malignant neoplasm of other urinary organs (urethra)	HCC 8	HCC 8
C79.51	Secondary malignant neoplasm of bone	HCC 8	HCC 8
C79.81	Secondary malignant neoplasm of breast	HCC 8	HCC 8
C79.89	Secondary malignant neoplasm of other specified sites	HCC 8	HCC 8

Urologic Metastatic Involvement: C79.11 (bladder) and C79.19 (urethra/other urinary organs) are particularly relevant for urology inpatient coders, as locally advanced vulvar cancers (FIGO IVA) frequently involve the distal urethra, proximal urethra, or bladder neck. When the surgeon or oncologist documents direct extension into or secondary malignant involvement of urologic structures, these codes must be captured alongside C51.9.

ICD-10-CM Code	Description	HCC v24	HCC v28
C52	Malignant neoplasm of vagina	HCC 11	HCC 17
C53.9	Malignant neoplasm of cervix uteri, unspecified	HCC 11	HCC 17
C67.9	Malignant neoplasm of bladder, unspecified	HCC 11	HCC 17
D07.2	Carcinoma in situ of vagina (VAIN III)	❌ No	—
D07.69	Carcinoma in situ of other female genital organs	❌ No	—

HPV Field Effect: Because vulvar SCC shares its HPV-driven etiology with cervical, vaginal, and anal malignancies, synchronous or metachronous cancers of the lower genital tract are not uncommon. When a second primary malignancy is documented and clinically confirmed, it should be coded separately. ICD-10-CM Official Guidelines allow coding of multiple primary malignancies when each is documented as a distinct primary — they are not combined under a single code.²

Pre-existing Conditions & Risk Factors

ICD-10-CM Code	Description	HCC
L90.0	Lichen sclerosus et atrophicus	❌ No
L43.9	Lichen planus, unspecified	❌ No
N90.0	VIN I	❌ No
N90.1	VIN II	❌ No
N90.2	VIN III (use when distinct from the invasive cancer being treated)	❌ No
B97.7	Papillomavirus as cause of diseases classified elsewhere (HPV)	❌ No
Z87.810	Personal history of HPV	❌ No
F17.210	Nicotine dependence, cigarettes, uncomplicated (smoking)	❌ No
B20	Human immunodeficiency virus (HIV) disease	HCC 1	HCC 1
Z21	Asymptomatic HIV infection status	HCC 1	HCC 1

High-Value Comorbidity Diagnoses (HCC-Relevant)

ICD-10-CM Code	Description	HCC v24	HCC v28
N18.30	CKD, stage 3, unspecified	HCC 137	HCC 329
N18.31	CKD, stage 3a	HCC 137	HCC 329
N18.32	CKD, stage 3b	HCC 137	HCC 329
N18.4	CKD, stage 4	HCC 137	HCC 329
N18.5	CKD, stage 5	HCC 136	HCC 328
N18.6	End stage renal disease	HCC 136	HCC 328
E11.65	Type 2 DM with hyperglycemia	HCC 19	HCC 37
E11.649	Type 2 DM with hypoglycemia, without coma	HCC 19	HCC 37
I50.9	Heart failure, unspecified	HCC 85	HCC 221
I50.32	Chronic diastolic heart failure	HCC 85	HCC 221
E66.01	Morbid (severe) obesity	HCC 22	HCC 48
A41.9	Sepsis, unspecified organism	HCC 2	HCC 2
D63.0	Anemia in neoplastic disease	❌ No (CC for MS-DRG)	—
E44.0	Moderate protein-calorie malnutrition	❌ No (MCC for MS-DRG)	—
E41	Nutritional marasmus (severe malnutrition)	❌ No (MCC for MS-DRG)	—
B20	HIV disease	HCC 1	HCC 1

ICD-10-CM Code	Description	HCC
T85.898A	Other specified complication of other internal prosthetic devices, initial encounter	❌ No
N99.89	Other postprocedural complications of genitourinary system	❌ No
I97.89	Other intraoperative and postprocedural complications of circulatory system	❌ No
L97.919	Non-pressure chronic ulcer of unspecified part of unspecified lower leg	❌ No
I89.0	Lymphedema, not elsewhere classified	❌ No
I89.1	Lymphangitis	❌ No
G89.29	Other chronic pain (chronic post-surgical pain)	❌ No
N39.0	Urinary tract infection	❌ No
T81.4XXA	Infection following a procedure, initial encounter	❌ No
T81.89XA	Other complications of procedures NEC, initial encounter	❌ No
Y83.9	Surgical procedure as cause of abnormal reaction, unspecified (external cause)	❌ No

ICD-10-CM Code	Description	HCC
Z51.11	Encounter for antineoplastic chemotherapy	❌ No
Z51.12	Encounter for antineoplastic immunotherapy	❌ No
Z51.0	Encounter for antineoplastic radiation therapy	❌ No
T45.1X5A	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter	❌ No
L58.9	Radiodermatitis, unspecified (radiation skin injury)	❌ No
K62.7	Radiation proctitis	❌ No
N30.40	Radiation cystitis without hematuria	❌ No
N30.41	Radiation cystitis with hematuria	❌ No
M54.5	Low back pain (post-radiation/surgical sequela — specify etiology)	❌ No

Radiation Cystitis Coding — Urologic Relevance: Patients with vulvar cancer who receive pelvic radiation therapy are at significant risk for radiation cystitis (N30.40, N30.41). When a urology consult is generated during a vulvar cancer admission for hematuria or voiding dysfunction secondary to radiation injury, these codes become directly relevant to inpatient urology coding workflow.

Personal History & Follow-Up Z-Codes

ICD-10-CM Code	Description	HCC
Z85.42	Personal history of malignant neoplasm of vulva	❌ No
Z85.44	Personal history of malignant neoplasm of other female genital organs	❌ No
Z08	Encounter for follow-up after completed treatment for malignant neoplasm	❌ No
Z12.72	Encounter for screening for malignant neoplasm of vagina	❌ No
Z12.79	Encounter for screening, other malignant neoplasms of other genitourinary organs	❌ No
Z79.818	Long-term use of agents affecting estrogen receptors (hormonal therapy)	❌ No
Z79.899	Other long-term drug therapy (checkpoint inhibitors, PARP inhibitors)	❌ No
Z90.710	Acquired absence of cervix and uterus (if prior hysterectomy)	❌ No
Z90.711	Acquired absence of uterus with remaining cervical stump	❌ No
Z96.0	Presence of urogenital implants (e.g., AUS or sling if placed post-treatment)	❌ No

Z85.42 — When to Use: Z85.42 replaces C51.9 as the active cancer code only after the vulvar malignancy has been definitively treated and the patient is considered in remission or disease-free at the conclusion of treatment. During active treatment encounters — including surgery, chemotherapy, radiation, or any admission directly related to the cancer — C51.9 remains the principal or relevant secondary diagnosis. Do not prematurely assign Z85.42 while active treatment is ongoing.

🏨 MS-DRG Assignment

Inpatient Coding Note: C51.9 is an ICD-10-CM diagnosis code that — in the inpatient setting — works in conjunction with ICD-10-PCS procedure codes to drive MS-DRG assignment. The surgical and medical treatment of vulvar malignancy falls primarily under MDC 13 (Diseases & Disorders of the Female Reproductive System), though cases complicated by sepsis, systemic disease, or multi-organ involvement may shift to other MDCs.

Primary MS-DRGs — MDC 13 (Female Reproductive System)

When OR Procedure Performed (Surgery for Vulvar Cancer):

MS-DRG	Description	Approx. Relative Weight³
742	Uterine & Adnexa Procedures for Ovarian or Adnexal Malignancy w/ MCC	~5.10
743	Uterine & Adnexa Procedures for Ovarian or Adnexal Malignancy w/ CC	~2.90
744	Uterine & Adnexa Procedures for Ovarian or Adnexal Malignancy w/o CC/MCC	~1.80
751	Other Female Reproductive System O.R. Procedures w/ MCC	~4.20
752	Other Female Reproductive System O.R. Procedures w/ CC	~2.20
753	Other Female Reproductive System O.R. Procedures w/o CC/MCC	~1.40

When No OR Procedure / Medical Management Only:

MS-DRG	Description	Approx. Relative Weight³
754	Malignancy, Female Reproductive System w/ MCC	~2.10
755	Malignancy, Female Reproductive System w/ CC	~1.20
756	Malignancy, Female Reproductive System w/o CC/MCC	~0.75

DRG Determination Logic: The specific MS-DRG assigned for a vulvar cancer admission is determined by:

Principal Diagnosis — C51.9 or a more specific C51.x code

ICD-10-PCS Procedure Codes — whether an OR procedure (vulvectomy, lymphadenectomy) was performed and the root operation/approach

CC/MCC Status — presence and accurate coding of complications and comorbidities

A radical vulvectomy with bilateral inguinofemoral lymphadenectomy typically groups to DRG 742-744 or 751-753 depending on the grouper’s classification of the specific ICD-10-PCS procedure codes used. DRGs 754-756 apply when the admission is managed medically (e.g., pain management, chemotherapy administration, complication management without return to OR).

Sepsis as Principal Diagnosis (MDC 18 Shift)

When vulvar cancer is complicated by sepsis (e.g., wound infection post-vulvectomy progressing to sepsis, infected inguinal wound, infected pelvic collection) and the physician documents sepsis as the principal diagnosis (reason chiefly responsible for the admission after study), the case shifts from MDC 13 to MDC 18 (Infectious & Parasitic Diseases):

MS-DRG	Description	Approx. Relative Weight³
871	Septicemia or Severe Sepsis w/ MV >96 hours	~6.50
872	Septicemia or Severe Sepsis w/o MV >96 hrs w/ MCC	~1.90
873	Septicemia or Severe Sepsis w/o MV >96 hrs w/o MCC	~1.10

CDI Opportunity: Post-vulvectomy wound infections with systemic signs that meet sepsis criteria should prompt a physician query to clarify whether the clinical picture represents sepsis (A41.xx) — which has HCC and MCC implications — or a localized wound/surgical site infection. The distinction can shift a case from DRG 752/753 to DRG 872, representing a substantial difference in facility reimbursement.

ICD-10-PCS Procedure Codes (Inpatient Facility Billing)

For inpatient facility (UB-04) billing, ICD-10-PCS codes — not CPT codes — drive DRG assignment. The following ICD-10-PCS codes represent common inpatient procedures performed for vulvar malignancy:

Root Operation: Resection (T) — Complete removal of a body part

ICD-10-PCS Code	Description
0UTC0ZZ	Resection of vulva, open approach
0UTC4ZZ	Resection of vulva, percutaneous endoscopic approach (laparoscopic assist — uncommon)
0UTM0ZZ	Resection of clitoris, open approach

Root Operation: Excision (B) — Partial removal (simple/partial vulvectomy)

ICD-10-PCS Code	Description
0UBC0ZZ	Excision of vulva, open approach, no qualifier (therapeutic)
0UBC0ZX	Excision of vulva, open approach, diagnostic qualifier (biopsy)
0UBM0ZZ	Excision of clitoris, open approach

Resection vs. Excision: In ICD-10-PCS:

Resection (T) = complete removal of the entire body part (radical complete vulvectomy = entire vulva removed)

Excision (B) = partial removal, cutting out a portion of the body part (partial vulvectomy; simple or radical partial) The distinction between Excision and Resection in ICD-10-PCS for vulvectomy procedures is a frequent source of inpatient coding questions. The operative report must document whether the procedure was partial (Excision) or complete/total (Resection). Clinical documentation of “radical complete vulvectomy” supports Resection (T); “radical partial vulvectomy” supports Excision (B).²

Lymph Node Dissection (Coded Separately):

ICD-10-PCS Code	Description
07TH0ZZ	Resection of right inguinal lymphatic, open approach
07TJ0ZZ	Resection of left inguinal lymphatic, open approach
07TC0ZZ	Resection of pelvic lymphatic, open approach
07TG0ZZ	Resection of aortic lymphatic, open approach
07BH0ZX	Excision of right inguinal lymphatic, open, diagnostic (sentinel node biopsy)
07BJ0ZX	Excision of left inguinal lymphatic, open, diagnostic (sentinel node biopsy)

Sentinel Lymph Node Biopsy (SLNB): In early-stage vulvar cancer, sentinel lymph node biopsy (rather than full inguinofemoral lymphadenectomy) is increasingly standard. SLNB is coded as Excision (B) with diagnostic qualifier (X) in ICD-10-PCS, reflecting the sampling rather than complete lymphatic resection. The root operation for full lymphadenectomy is Resection (T) (complete removal of the lymph node chain).²

💊 Associated CPT Procedure Codes (Physician/Professional Fee Billing)

The following CPT procedure codes are commonly used for the surgical treatment of vulvar malignancy. wRVU values, global periods, and assistant surgeon payability are properties of the CPT procedure code, not of C51.9. Values are approximate — verify with current CMS MPFS.⁴

Vulvectomy CPT Code Family

CPT Code	Description	wRVU (Approx.)	Global Period	Asst. Payable
56620	Vulvectomy, simple; partial	~8.00	090	✅ Yes
56625	Vulvectomy, simple; complete	~11.50	090	✅ Yes
56630	Vulvectomy, radical; partial	~18.50	090	✅ Yes
56631	Vulvectomy, radical; partial + unilateral inguinofemoral LND	~22.00	090	✅ Yes
56632	Vulvectomy, radical; partial + bilateral inguinofemoral LND	~27.50	090	✅ Yes
56633	Vulvectomy, radical; complete	~21.00	090	✅ Yes
56634	Vulvectomy, radical; complete + unilateral inguinofemoral LND	~25.50	090	✅ Yes
56637	Vulvectomy, radical; complete + bilateral inguinofemoral LND	~31.00	090	✅ Yes
56640	Vulvectomy, radical; complete + inguinofemoral, iliac & pelvic LND	~35.00	090	✅ Yes

Simple vs. Radical Vulvectomy (CPT Distinction):

Simple vulvectomy (56620, 56625): Removal of skin and superficial subcutaneous tissue; does not include deep subcutaneous tissue or fascial removal

Radical vulvectomy (56630-56640): Removal of skin, deep subcutaneous tissue, and often including underlying fascia; much more extensive resection

The operative report must contain language sufficient to distinguish simple from radical — look for depth of resection, tissue planes, and fascial involvement. “Wide local excision” of the vulva is generally coded as a simple partial vulvectomy (56620) unless documentation describes radical resection planes.

Partial vs. Complete (CPT Distinction):

Partial: Less than total/complete vulvar removal; a portion of the vulvar complex is spared

Complete: Total vulvectomy — the entire vulvar complex (bilateral labia majora, labia minora, clitoris, and perineal body) is removed

Associated Diagnostic & Staging Procedures

CPT Code	Description	wRVU (Approx.)	Global Period	Asst. Payable
57100	Biopsy of vaginal mucosa; simple	~1.20	000	❌ No
56605	Biopsy of vulva or perineum; one lesion	~1.50	000	❌ No
56606	Biopsy of vulva or perineum; each separate additional lesion	~0.80	ZZZ	❌ No
38525	Biopsy or excision of lymph node; deep axillary node	~5.50	010	❌ No
38542	Dissection, deep jugular node(s)	~7.00	090	✅ Yes
38562	Limited lymphadenectomy for staging; pelvic/para-aortic	~14.50	090	✅ Yes
38765	Inguinofemoral lymphadenectomy, superficial; unilateral	~12.50	090	✅ Yes
38760	Inguinofemoral node dissection	~12.00	090	✅ Yes
38900	Intraoperative identification of sentinel lymph node(s)	Add-on	ZZZ	N/A

Reconstruction & Wound Management

CPT Code	Description	wRVU (Approx.)	Global
15734	Muscle, myocutaneous, or fasciocutaneous flap; trunk	~22.00	090
15738	Muscle, myocutaneous, or fasciocutaneous flap; lower extremity	~25.00	090
15240	Full thickness graft; scalp, arms, or legs — may apply to vulva reconstruction	~9.00	090
14000	Adjacent tissue transfer/rearrangement, trunk; 10 sq cm or less	~7.50	090
14001	Adjacent tissue transfer/rearrangement, trunk; 10.1-30 sq cm	~10.00	090
97597	Debridement, open wound; first 20 sq cm	~1.20	000

Radiation Oncology (When Applicable)

CPT Code	Description
77261	Therapeutic radiology treatment planning; simple
77262	Therapeutic radiology treatment planning; intermediate
77263	Therapeutic radiology treatment planning; complex
77301	IMRT planning
77385	IMRT delivery, simple
77386	IMRT delivery, complex
96413	Chemotherapy administration, intravenous infusion; first hour
96415	Chemotherapy IV infusion; each additional hour
J9070	Cisplatin injection (commonly used as radiosensitizer in vulvar cancer)

🏷️ Modifiers Applicable in C51.9 Encounters

These modifiers apply to the CPT procedure codes associated with vulvar cancer treatment, not to the ICD-10-CM diagnosis code C51.9 itself.

Modifier	Description	Application Context
-22	Increased procedural services	Radical vulvectomy with extensive reconstruction; locally advanced disease requiring complex multi-organ dissection; prior radiation field complicating tissue planes; extremely obese patient
-51	Multiple procedures	When vulvectomy (56633/56637) is performed alongside separate reconstructive procedures (tissue flap, skin graft) or urologic procedures (urethral repair); apply to lesser-valued code
-52	Reduced services	Planned procedure not completed as intended (e.g., radical vulvectomy planned but converted to wide local excision due to intraoperative findings)
-53	Discontinued procedure	Procedure initiated and terminated before completion due to patient safety
-58	Staged or related procedure	Planned second-stage procedure within global period (e.g., delayed reconstruction after initial radical vulvectomy; planned re-excision for positive margins)
-62	Two surgeons	Radical vulvectomy with concurrent urologic procedure (e.g., gynecologic oncologist + urologist performing concurrent urethral reconstruction or cystectomy for FIGO IVA disease)
-78	Unplanned return to OR, related procedure	Return to OR during 90-day global for wound dehiscence, hematoma, or flap revision
-79	Unrelated procedure during global period	Unrelated surgery during the 90-day global period
-80	Assistant surgeon	Payable for radical vulvectomy codes (56630-56640); assistant bills with -80
-AS	Non-physician assistant at surgery	PA/NP as assistant at surgery under Medicare
-24	Unrelated E/M during global period	Unrelated office visit or E/M during 90-day global
-25	Significant, separately identifiable E/M same day	Separate E/M for distinct problem on day of procedure
-RT / -LT	Right/Left side	Applicable to unilateral procedures (e.g., unilateral inguinofemoral lymphadenectomy — specify side)
-50	Bilateral procedure	Bilateral inguinofemoral lymphadenectomy when performed as a bilateral procedure (verify vs. code 56632 or 56637 which already describe bilateral LND — do not add -50 to codes that already include bilateral in the descriptor)

📖 Coding Examples

Example 1 - New Diagnosis of Vulvar Cancer, Outpatient Biopsy

A 68-year-old female presents with a vulvar lesion noted on routine gynecologic exam. Colposcopy-directed biopsy of the right labium majus is performed. Pathology returns invasive squamous cell carcinoma of the right labium majus. The physician documents “squamous cell carcinoma, right labium majus.”

CPT: 56605 (biopsy of vulva, one lesion) ICD-10-CM (First Listed): C51.0 (malignant neoplasm of labium majus — not C51.9; sub-site is specified as labium majus)

✅ Code Selection Tip: When the operative/pathology report specifies the sub-site (labium majus, labium minus, clitoris), always code the more specific C51.x code rather than C51.9. C51.9 should only be used when documentation genuinely does not specify the sub-site or the lesion is described only as “vulvar cancer” without further anatomic detail.

Example 2 - Inpatient Radical Complete Vulvectomy with Bilateral Inguinofemoral Lymphadenectomy

A 72-year-old female with FIGO Stage IIB squamous cell carcinoma of the vulva, clinically unresectable initially, has undergone neoadjuvant chemoradiation and now presents for planned definitive surgery. She undergoes radical complete vulvectomy with bilateral inguinofemoral lymphadenectomy. Final pathology: ypT2N1aMx, two of fourteen lymph nodes positive for metastatic squamous cell carcinoma (right inguinal). She has CKD stage 3b (N18.32) and T2DM with hyperglycemia (E11.65) managed during the admission.

CPT (Surgeon): 56637 (vulvectomy, radical; complete, with bilateral inguinofemoral lymphadenectomy) Principal Diagnosis: C51.9 (malignant neoplasm of vulva, unspecified — operative note does not specify a single sub-site; overlapping disease documented as “vulva”) Secondary Diagnoses:

C77.4 (secondary malignant neoplasm of inguinal and lower limb lymph nodes — positive nodes confirmed by pathology) — HCC 8
N18.32 (CKD, stage 3b) — HCC 137; CC for MS-DRG
E11.65 (T2DM with hyperglycemia) — HCC 19; CC for MS-DRG
Z92.3 (personal history of irradiation — prior chemoradiation documented)

ICD-10-PCS Procedures:

0UTC0ZZ (Resection of vulva, open approach — complete vulvectomy = resection of entire body part)
07TH0ZZ (Resection of right inguinal lymphatic, open — bilateral inguinofemoral LND)
07TJ0ZZ (Resection of left inguinal lymphatic, open)

MS-DRG: Likely DRG 742 (Uterine and Adnexa Procedures for Ovarian or Adnexal Malignancy w/ MCC) or DRG 751 (Other Female Reproductive System O.R. Procedures w/ MCC) — confirm with grouper. N18.32 (CC) + E11.65 (CC) may combine to trigger MCC tier in some grouper logic; confirm current-year grouper behavior.

⚠️ HCC Escalation from C77.4: The positive inguinal lymph nodes with confirmed metastatic disease elevate the HCC from HCC 11 (C51.9) to HCC 8 (C77.4 — Metastatic Cancer). This is a significant RAF increase. Pathology must confirm nodal metastasis and the treating physician must acknowledge the finding in documentation for C77.4 to be coded.

Example 3 - Locally Advanced Vulvar Cancer with Urethral Involvement (Urologic Coding Relevance)

A 65-year-old female with a 4.5 cm vulvar SCC involving the distal and mid-urethra (FIGO Stage IVA) is admitted for exenterative surgery. The gynecologic oncology and urology teams perform a modified radical vulvectomy with bilateral inguinofemoral lymphadenectomy, partial urethral resection, and urethral reconstruction with Martius flap. The urologist performs the urethral dissection, resection, and reconstruction components; the gynecologic oncologist performs the vulvectomy and lymphadenectomy.

CPT (Gynecologic Oncologist):

56637--62 (radical complete vulvectomy with bilateral inguinofemoral lymphadenectomy — co-surgeon)

CPT (Urologist):

53400--62 (urethroplasty; first stage, for fistula, diverticulum, or stricture) or applicable urethral reconstruction code — co-surgeon

Principal Diagnosis: C51.9 (malignant neoplasm of vulva, unspecified — extensive, overlapping) Secondary Diagnoses:

C79.19 (secondary malignant neoplasm of other urinary organs — urethral involvement) — HCC 8
Additional relevant comorbidities as documented

✅ Co-Surgeon Billing (-62): When two surgeons of different specialties each perform distinct, separately documented components of a combined procedure — the gynecologic oncologist performing the vulvectomy/lymphadenectomy and the urologist performing the urethral reconstruction — each surgeon bills their respective CPT code with modifier -62. Each surgeon’s operative note must clearly delineate their specific contribution. C79.19 adds HCC 8 (Metastatic Cancer — secondary urethral malignancy) to the encounter, substantially impacting risk adjustment.

Example 4 - VIN III vs. Invasive Carcinoma (Coding Distinction)

Scenario A: Pathology returns “VIN III / High-grade squamous intraepithelial lesion (HSIL) of the vulva, no invasion identified.” Scenario B: Pathology returns “Invasive squamous cell carcinoma of the vulva, depth of invasion 2.1 mm.”

Scenario A CPT: 56620 (vulvectomy, simple; partial — wide local excision for VIN III) Scenario A ICD-10-CM: D07.1 (carcinoma in situ of vulva) — NOT C51.9; invasion is not present; this is in situ disease

Scenario B CPT: 56630 (vulvectomy, radical; partial — for invasive SCC) Scenario B ICD-10-CM: C51.9 (malignant neoplasm of vulva — invasive; now C51.x applies) — or more specific C51 code if sub-site documented

❌ Critical Distinction: D07.1 and C51.9 are never interchangeable. The presence or absence of stromal invasion — confirmed by pathology — is the determinative factor. Do not assign C51.9 for VIN III / carcinoma in situ diagnoses, even “carcinoma in situ” language; D07.1 is the correct code for non-invasive vulvar carcinoma. Code C51.9 only when pathology confirms invasion through the basement membrane.

Example 5 - Post-Treatment Surveillance Visit (History Code)

A 71-year-old female, 18 months post radical vulvectomy for SCC of the vulva, presents for routine surveillance examination. Physical exam reveals no evidence of recurrent or residual disease. No intervention performed today.

E/M: 99214 or 99215 (established patient outpatient visit) ICD-10-CM (First Listed): Z08 (encounter for follow-up examination after completed treatment for malignant neoplasm) Secondary: Z85.42 (personal history of malignant neoplasm of vulva)

✅ When the cancer is considered treated and the patient is disease-free, C51.9 is not re-coded. Z08 and Z85.42 are the appropriate codes for surveillance visits. If surveillance imaging or exam reveals recurrence, C51.9 (or the appropriate recurrence code) is reinstated as the active diagnosis. Note that the 90-day global period of the vulvectomy has long expired at 18 months — the E/M visit is independently billable.

Example 6 - Radiation Cystitis in Vulvar Cancer Patient (Urologic Relevance)

A 69-year-old female with known vulvar SCC (C51.9), currently undergoing concurrent cisplatin chemoradiation to the pelvis and vulva, is admitted with gross hematuria. Cystoscopy reveals diffuse mucosal hemorrhage consistent with radiation cystitis. No tumor involvement of the bladder is identified. The urologist performs fulguration of bleeding vessels (52214) and bladder irrigation.

CPT (Urologist): 52214 (cystourethroscopy with fulguration of trigone, bladder neck, prostatic fossa, urethra, or periurethral glands) Principal Diagnosis: N30.41 (radiation cystitis with hematuria — reason for this admission/encounter) Secondary Diagnoses:

C51.9 (underlying vulvar malignancy — still active; undergoing treatment) — HCC 11
R31.0 (gross hematuria — symptom integral to radiation cystitis; may be omitted per UHDDS guidelines as integral to the principal diagnosis)
Z51.0 (encounter for antineoplastic radiation therapy — context for radiation etiology)

✅ Principal Diagnosis: Radiation cystitis (N30.41) is the reason chiefly responsible for the admission (the hematuria/cystitis, not the underlying malignancy per se). C51.9 is coded as an important secondary diagnosis. This scenario directly intersects with urology inpatient coding workflow — the urologist performing the cystoscopy and fulguration generates the professional fee claim while the inpatient facility claim captures the DRG-driving diagnosis/procedure combination.

Example 7 - Inpatient Chemotherapy Administration for Metastatic Vulvar Cancer

A 74-year-old female with stage IVB vulvar SCC with inguinal and pelvic lymph node metastases and a small pulmonary nodule (suspected metastasis pending biopsy) is admitted for initiation of systemic chemotherapy with carboplatin and paclitaxel.

Principal Diagnosis: C51.9 (malignant neoplasm of vulva — active; reason for admission and treatment) Secondary Diagnoses:

C77.4 (secondary malignant neoplasm of inguinal lymph nodes — confirmed) — HCC 8
C77.5 (secondary malignant neoplasm of intrapelvic lymph nodes — confirmed) — HCC 8
C79.89 (suspected pulmonary metastasis — pending confirmation; for inpatient, uncertain diagnoses may be coded if documented as such at discharge — query physician for clarification at discharge)²
Relevant comorbidities as documented

CPT (Oncology/Chemotherapy):

96413 (chemotherapy IV infusion, first hour)
96415 (chemotherapy IV infusion, each additional hour — × multiple)
J9045 (carboplatin injection — HCPCS drug code; billed per dose)
J9264 (paclitaxel — HCPCS drug code)

MS-DRG: Likely DRG 754 (Malignancy, Female Reproductive System w/ MCC) or DRG 755 (w/ CC) — no OR procedure performed; medical management only. C77.4 (metastatic disease) as secondary diagnosis; confirm CC/MCC status with current-year grouper.

Inpatient Coding Guidance — Uncertain Diagnosis: For the suspected pulmonary metastasis, inpatient coding guidelines allow coding of uncertain diagnoses (qualified as “possible,” “probable,” “suspected,” “likely”) when documented by the physician at the time of discharge. This is a fundamental difference from outpatient coding guidelines, which prohibit coding uncertain diagnoses. If the physician documents “probable pulmonary metastasis” or “suspected metastatic pulmonary nodule” in the discharge summary, C79.1x may be appropriately coded for the inpatient claim.²

Code	Description
C51.0	Malignant neoplasm of labium majus
C51.1	Malignant neoplasm of labium minus
C51.2	Malignant neoplasm of clitoris
C51.8	Malignant neoplasm of overlapping sites of vulva
C52	Malignant neoplasm of vagina
C53.9	Malignant neoplasm of cervix uteri, unspecified
D07.1	Carcinoma in situ of vulva (VIN III / HSIL-V)
N90.2	Vulvar intraepithelial neoplasia III (VIN III — non-invasive)
L90.0	Lichen sclerosus et atrophicus
Z85.42	Personal history of malignant neoplasm of vulva
C77.4	Secondary malignant neoplasm of inguinal and lower limb lymph nodes
C79.11	Secondary malignant neoplasm of bladder
C79.19	Secondary malignant neoplasm of other urinary organs
N30.41	Radiation cystitis with hematuria
I89.0	Lymphedema (post-inguinal node dissection)

Associated CPT Procedure Codes

Code	Description
56605	Biopsy of vulva, one lesion
56606	Biopsy of vulva, each additional lesion
56620	Vulvectomy, simple; partial
56625	Vulvectomy, simple; complete
56630	Vulvectomy, radical; partial
56631	Vulvectomy, radical; partial + unilateral inguinofemoral LND
56632	Vulvectomy, radical; partial + bilateral inguinofemoral LND
56633	Vulvectomy, radical; complete
56634	Vulvectomy, radical; complete + unilateral inguinofemoral LND
56637	Vulvectomy, radical; complete + bilateral inguinofemoral LND
56640	Vulvectomy, radical; complete + inguinofemoral, iliac & pelvic LND
38760	Inguinofemoral node dissection
38765	Inguinofemoral LND, superficial, unilateral
38900	Sentinel lymph node ID (intraoperative)
52214	Cystoscopy with fulguration (for radiation cystitis management)
52000	Cystourethroscopy (for urologic evaluation of suspected bladder/urethral involvement)
77386	IMRT delivery, complex (pelvic radiation)
96413	Chemotherapy IV infusion, first hour
88309	Surgical pathology Level VI — vulvectomy specimen

📝 Clinical & Documentation Tips for Coders

Specificity first: C51.9 is the code of last resort within the C51 category. Always review pathology reports, operative notes, and physician documentation for sub-site specification before defaulting to the unspecified code. If the pathology report states “labium majus” — use C51.0. If the operative report states “clitoris” — use C51.2. The unspecified code should be used only when sub-site is genuinely absent from all available documentation.
In situ vs. invasive is a binary, non-negotiable distinction: D07.1 (in situ) and C51.9 (invasive) are not interchangeable under any circumstances. Pathology confirmation of invasion is required for C51.9. If pathology reports “VIN III” or “HSIL” without documenting invasion, the diagnosis is D07.1 — query the pathologist or treating physician if clinical documentation conflicts with pathology results.
Inpatient uncertain diagnosis privilege: For inpatient cases, the ICD-10-CM Official Guidelines allow coding of diagnoses qualified as “possible,” “probable,” “suspected,” or “likely” when documented at discharge. This is frequently relevant for metastatic vulvar cancer cases where imaging suggests but does not confirm secondary lesions. Code the uncertain metastatic diagnosis (e.g., C79.51 for “probable bone metastasis”) for inpatient claims when documented as such — but never for outpatient claims.
Lymphedema post-inguinofemoral dissection (I89.0): This is a common, significant long-term complication of inguinofemoral lymphadenectomy for vulvar cancer. When documented and treated during the inpatient encounter, I89.0 should be coded as a secondary diagnosis. It is not an HCC code but contributes to complete clinical documentation and may affect quality metrics.
Urologic complications are directly relevant to urology inpatient coders: Vulvar cancer and its treatment create multiple urologic coding opportunities — radiation cystitis, urethral stricture/injury, fistula formation (vesicovaginal, urethrovaginal), hydronephrosis from pelvic disease, and post-surgical urinary incontinence. When a urology consult is generated during a vulvar cancer admission, the coder should capture both the underlying malignancy (C51.9) and the specific urologic complication or finding that prompted the consultation.
Lymph node metastasis HCC escalation: Positive inguinal nodes on final pathology (C77.4) elevate the HCC from HCC 11 to HCC 8 (Metastatic Cancer), a major RAF increase. This finding is frequently available only after the surgical admission has been coded based on the pre-operative diagnosis. A coding review process that incorporates final pathology results (which may return after initial coding) is important for accurate HCC capture in vulvar cancer cases.
CDI query opportunities for DRG optimization:
- CKD staging (N18.3x-N18.6) — CC/MCC
- Malnutrition (cancer cachexia, weight loss, hypoalbuminemia → E44.0, E41) — CC/MCC
- Anemia etiology (D63.0 anemia in neoplastic disease vs. D62 acute blood loss anemia) — CC status
- Sepsis vs. wound infection (post-vulvectomy complications)
- DVT/PE (post-pelvic surgery high risk) — CC/MCC
- Severity of lymphedema and wound complications
Radiation oncology coding intersection: When vulvar cancer patients receive concurrent chemoradiation, the radiation oncology codes (77261-77386) and chemotherapy administration codes (96413, 96415) generate separately billable professional fee claims. These claims also use C51.9 as the associated diagnosis. Ensure consistent diagnosis coding across all treating providers involved in the care episode.

📚 References

CMS HCC Risk Adjustment Model - Announcement and Call Letter. cms.gov/medicare/health-plans/medicareadvtgspecratestats ↩
AHA Coding Clinic for ICD-10-CM/PCS. American Hospital Association. ahacodingclinic.org ↩ ↩² ↩³ ↩⁴ ↩⁵
CMS MS-DRG Definitions Manual & IPPS Final Rule. cms.gov/medicare/medicare-fee-for-service-payment/acuteinpatientpps ↩ ↩² ↩³
CMS Physician Fee Schedule - MPFS Look-Up Tool. cms.gov/medicare/physician-fee-schedule ↩

Explorer

C51.9